CRISPR Therapeutics AG
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CRISPR Therapeutics AG
Building on Oxbryta, which is already approved in the US for the rare blood disorder, Global Blood Therapeutics has licensed two sickle cell disease programs from Sanofi.
Just three of the 13 applications that the European Medicines Agency most recently reviewed for entry onto its priority medicines scheme made the grade.
Last year saw the number of applications accepted onto the European Medicines Agency’s priority medicines scheme inch up and the notoriously high rejection rate for applications drop.
- Drug Delivery
- Gene Therapy, Cell Therapy
- Large Molecule
Drug Discovery Tools
- Other Names / Subsidiaries
- Casebia Therapeutics